本帖最后由 老马 于 2012-1-13 21:20 编辑 $ k5 t, [% A6 T: c- `' D* M
4 h, ^2 d8 K( [% d6 x( S- R0 `3 J
爱必妥和阿瓦斯丁的比较
7 Q7 b. A" f% }) O
- M+ t Y9 i8 b- X [, Zhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 F0 y; u R8 A' N$ b
2 l7 _* [6 c5 J; h
3 A' I/ T3 s% E' h$ Z/ T9 J$ d+ s
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/$ H: `1 v* K7 k- S. X- M
==================================================' f8 j7 x. t8 {3 q( T
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ H$ Z0 a6 ~3 K8 O' ]$ f- [: [ X
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% L2 P6 [ e+ r: h. m+ r# O' bResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.& n- D4 o# o( U, K" b0 E. x
|